02096.HK
Simcere Pharmaceutical Group Limited
HKSE · Healthcare · Biotechnology · CN
HKD 11.17
−0.89%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 11.07
From 52W high−20.33%
Volume12.33M
Market capHKD 28.07B
P/E (TTM)15.7x
P/S (TTM)2.8x
Div yield1.85%
Key dataSep 18, 2026
Open
HKD 11.07
From 52W high
−20.33%
Volume
12.33M
Market cap
HKD 28.07B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
10.4x
P/E (TTM)
15.7x
RSI (14)
41.3
MomentumView details →
1D Return
−0.89%
YTD Return
−6.68%
Similar companies
Latest newsMore news →
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.20d agoSimcere Pharmaceutical announced that Zhou Yunshu stepped down as CEO and was appointed President, while founder Ren Jinsheng resumed the role of CEO, effective August 20, 2026.30d ago